Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04278989 · ClinicalTrials.gov registry record · Early Phase 1
Inhibition of Oral Tumorigenesis by Antitumor B
A Early Phase 1 study, sponsored by Medical College of Wisconsin.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 30
- Enrollment target
NCT04278989 is a Early Phase 1 study that has completed, run by Medical College of Wisconsin. The registered enrollment target is 30 participants.
The verdict
NCT04278989, a Early Phase 1 study, has completed, sponsored by Medical College of Wisconsin.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
This is a window of opportunity study of Anti-tumor B (ATB). Anti-tumor B is a botanical agent composed of six Chinese herbs: Sophora tonkinensis, Polygonum bistorta, Prunella vulgaris, Sonchus brachyotus, Dictamnus dasycarpus, and Dioscorea bulbifera.
Interventions
- DRUG Anti-tumor B
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2022-04-22 |
| Est. Completion | 2025-06-05 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04278989
The ClinicalTrials.gov registry entry for NCT04278989 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical College of Wisconsin, which has 447 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Anti-tumor B is the first listed.
NCT04278989 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04278989 about?
NCT04278989 is a clinical study titled "Inhibition of Oral Tumorigenesis by Antitumor B". This is a window of opportunity study of Anti-tumor B (ATB). Anti-tumor B is a botanical agent composed of six Chinese herbs: Sophora tonkinensis, Polygonum bistorta, Prunella vulgaris, Sonchus brachyotus, Dictamnus dasycarpus, and Dioscorea bulbifera.
What is the current status of trial NCT04278989?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 30 participants. The study started on 2022-04-22. Estimated completion is 2025-06-05.
What interventions are being tested in trial NCT04278989?
The interventions under investigation include: Anti-tumor B (DRUG).
Who is sponsoring clinical trial NCT04278989?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.